Literature DB >> 21495689

N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.

Ashwini K Banala1, Benjamin A Levy, Sameer S Khatri, Cheryse A Furman, Rebecca A Roof, Yogesh Mishra, Suzy A Griffin, David R Sibley, Robert R Luedtke, Amy Hauck Newman.   

Abstract

N-(3-fluoro-4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazine-1-yl)butyl)arylcarboxamides were prepared and evaluated for binding and function at dopamine D3 receptors (D3Rs) and dopamine D2 receptors (D2Rs). In this series, we discovered some of the most D3R selective compounds reported to date (e.g., 8d and 8j, >1000-fold D3R-selective over D2R). In addition, chimeric receptor studies further identified the second extracellular (E2) loop as an important contributor to D3R binding selectivity. Further, compounds lacking the carbonyl group in the amide linker were synthesized, and while these amine-linked analogues bound with similar affinities to the amides at D2R, this modification dramatically reduced binding affinities at D3R by >100-fold (e.g., D3R K(i) for 15b = 393 vs for 8j = 2.6 nM), resulting in compounds with significantly reduced D3R selectivity. This study supports a pivotal role for the D3R E2 loop and the carbonyl group in the 4-phenylpiperazine class of compounds and further reveals a point of separation between structure-activity relationships at D3R and D2R.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21495689      PMCID: PMC3100590          DOI: 10.1021/jm200288r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  32 in total

1.  Crystal structure of rhodopsin: A G protein-coupled receptor.

Authors:  K Palczewski; T Kumasaka; T Hori; C A Behnke; H Motoshima; B A Fox; I Le Trong; D C Teller; T Okada; R E Stenkamp; M Yamamoto; M Miyano
Journal:  Science       Date:  2000-08-04       Impact factor: 47.728

2.  The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle.

Authors:  L Shi; M M Simpson; J A Ballesteros; J A Javitch
Journal:  Biochemistry       Date:  2001-10-16       Impact factor: 3.162

3.  Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands.

Authors:  Wenhua Chu; Zhude Tu; Elizabeth McElveen; Jinbin Xu; Michelle Taylor; Robert R Luedtke; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

Review 4.  Localization and function of the D3 dopamine receptor.

Authors:  P Sokoloff; B Giros; M P Martres; M Andrieux; R Besancon; C Pilon; M L Bouthenet; E Souil; J C Schwartz
Journal:  Arzneimittelforschung       Date:  1992-02

Review 5.  Dopamine D3 receptor antagonists as therapeutic agents.

Authors:  Jeffrey N Joyce; Mark J Millan
Journal:  Drug Discov Today       Date:  2005-07-01       Impact factor: 7.851

6.  Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist.

Authors:  Ellen Y T Chien; Wei Liu; Qiang Zhao; Vsevolod Katritch; Gye Won Han; Michael A Hanson; Lei Shi; Amy Hauck Newman; Jonathan A Javitch; Vadim Cherezov; Raymond C Stevens
Journal:  Science       Date:  2010-11-19       Impact factor: 47.728

7.  Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.

Authors:  Gregory T Collins; Jeffrey M Witkin; Amy H Newman; Kjell A Svensson; Peter Grundt; Jianjing Cao; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-04-15       Impact factor: 4.030

8.  Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.

Authors:  Peter Grundt; Erin E Carlson; Jianjing Cao; Christina J Bennett; Elizabeth McElveen; Michelle Taylor; Robert R Luedtke; Amy Hauck Newman
Journal:  J Med Chem       Date:  2005-02-10       Impact factor: 7.446

9.  The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice.

Authors:  Lei Shi; Jonathan A Javitch
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-02       Impact factor: 11.205

10.  Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain.

Authors:  G Mengod; M T Villaró; G B Landwehrmeyer; M I Martinez-Mir; H B Niznik; R K Sunahara; P Seeman; B F O'Dowd; A Probst; J M Palacios
Journal:  Neurochem Int       Date:  1992-03       Impact factor: 3.921

View more
  34 in total

1.  Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.

Authors:  Mark Johnson; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2012-06-13       Impact factor: 7.446

2.  Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.

Authors:  Jennie L Conroy; R Benjamin Free; David R Sibley
Journal:  ACS Chem Neurosci       Date:  2015-02-20       Impact factor: 4.418

3.  Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor.

Authors:  R Benjamin Free; Lani S Chun; Amy E Moritz; Brittney N Miller; Trevor B Doyle; Jennie L Conroy; Adrian Padron; Julie A Meade; Jingbo Xiao; Xin Hu; Andrés E Dulcey; Yang Han; Lihua Duan; Steve Titus; Melanie Bryant-Genevier; Elena Barnaeva; Marc Ferrer; Jonathan A Javitch; Thijs Beuming; Lei Shi; Noel T Southall; Juan J Marugan; David R Sibley
Journal:  Mol Pharmacol       Date:  2014-04-22       Impact factor: 4.436

Review 4.  What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?

Authors:  Mayako Michino; Thijs Beuming; Prashant Donthamsetti; Amy Hauck Newman; Jonathan A Javitch; Lei Shi
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

5.  Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).

Authors:  Vivek Kumar; Amy E Moritz; Thomas M Keck; Alessandro Bonifazi; Michael P Ellenberger; Christopher D Sibley; R Benjamin Free; Lei Shi; J Robert Lane; David R Sibley; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-02-10       Impact factor: 7.446

6.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

7.  (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling.

Authors:  Julie A Meade; R Benjamin Free; Nicole R Miller; Lani S Chun; Trevor B Doyle; Amy E Moritz; Jennie L Conroy; Val J Watts; David R Sibley
Journal:  Psychopharmacology (Berl)       Date:  2014-09-18       Impact factor: 4.530

8.  Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.

Authors:  Cheryse A Furman; Rebecca A Roof; Amy E Moritz; Brittney N Miller; Trevor B Doyle; R Benjamin Free; Ashwini K Banala; Noel M Paul; Vivek Kumar; Christopher D Sibley; Amy Hauck Newman; David R Sibley
Journal:  Eur Neuropsychopharmacol       Date:  2014-11-29       Impact factor: 4.600

9.  Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor.

Authors:  Mayako Michino; Comfort A Boateng; Prashant Donthamsetti; Hideaki Yano; Oluyomi M Bakare; Alessandro Bonifazi; Michael P Ellenberger; Thomas M Keck; Vivek Kumar; Clare Zhu; Ravi Verma; Jeffrey R Deschamps; Jonathan A Javitch; Amy Hauck Newman; Lei Shi
Journal:  J Med Chem       Date:  2017-01-05       Impact factor: 7.446

10.  Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.

Authors:  Amy E Moritz; R Benjamin Free; Warren S Weiner; Emmanuel O Akano; Disha Gandhi; Ara Abramyan; Thomas M Keck; Marc Ferrer; Xin Hu; Noel Southall; Joseph Steiner; Jeffrey Aubé; Lei Shi; Kevin J Frankowski; David R Sibley
Journal:  J Med Chem       Date:  2020-05-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.